You are here: Industry Insights > Rituxan

News List

FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion pharmafile
November 30, 2018
The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to Celltrion and Teva’s Truxima.
Green light for Roche/AbbVie's chemo-free CLL treatment combo pharmatimes
November 05, 2018
Roche says a combination of Venclyxto and MabThera has been approved in the European Union for people with previously treated chronic...
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma fiercepharma
November 05, 2018
Celgene’s Revlimid may have slipped in tandem with Roche’s Rituxan in previously untreated follicular lymphoma patients. But in the second-line setting, the drug has a win.
Sales of Roche’s Rituxan Have Started to Decline as Biosimilars Thereof are Marketed 1℃
November 02, 2018
Celltrion and Teva Pharmaceutical released big news on October 11, 2018 that the Rituxan® (rituximab) biosimilar. After the marketing, CT-P10 will become the first Rituxan® (rituximab) biosimilar approved for marketing in the U.S.
FDA panel unanimously backs Celltrion's Rituxan biosimilar fiercepharma
October 11, 2018
Celltrion and its biosimilar marketing partner Teva may be on their way to challenging Roche’s top drug, Rituxan.
US delay for Celltrion's Rituxan, Herceptin biosimilars pharmatimes
July 18, 2018
The US Food and Drug Administration has rejected Celltrion’s submissions for biosimilars to Roche drugs Rituxan and Herceptin.
US widens scope of Rituxan to include life-threatening skin condition pharmatimes
July 10, 2018
Roche group Genentech has received US approval for Rituxan to treat moderate to severe pemphigus vulgaris (PV), giving patients access to the first new therapy for the condition in more than 60 years.
FDA Approves Genentech’s Rituxan (rituximab) for Pemphigus Vulgaris drugs
June 12, 2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV),
Out of the FDA doghouse, Celltrion again seeks Rituxan biosimilar nod fiercepharma
May 31, 2018
Celltrion, trying to get back on track with two biosimilars it shares with Teva, is returning to the FDA with its versions of the blockbuster cancer treatments.
How Roche Fine-tuned An Old Drug to Keep Making Profits bloomberg.com
August 24, 2017
The pharma company reformulated a cancer drug to treat MS and jacked up the price.

Previous page 1 2 3 Next page